$GNLX

GENELUX Corp

Genelux is a late clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat cancers. Its proprietary CHOICE platform uses vaccinia virus strains to develop product candidates intended to kill tumor cells and stimulate immune responses. Its lead candidate, Olvi-Vec, is being evaluated in clinical trials for platinum-resistant or refractory ovarian cancer, recurrent non-small cell lung cancer and recurrent small cell lung cancer. Genelux also has a library of more than 500 engineered vaccinia virus candidates. Genelux conducts research and development, clinical testing and manufacturing, including at its cGMP facility in San Diego, California. It earns license-related payments and royalties under an agreement granting Newsoara rights to develop and commercialize licensed products in mainland China, Taiwan, Hong Kong and Macau. Its headquarters are in Westlake Village, California.

0
0
2
—
$9K
Yu Yong
0%
See all $GNLX insider activity →
Med

Genelux Corporation (GNLX) Reports $10.3M Q3 Net Loss; Cash Runway Into 1Q27

Genelux (GNLX) reported a Q3 2026 net loss of $10.3M, or $0.23 per share, compared to $8.0M, or $0.21 per share, in Q3 2025. The company has $15.5M in cash and expects funding into 1Q27. Genelux is in late clinical-stage trials for ovarian and lung cancer, with key data expected in 2H26.

GENELUX Corp (GNLX): Submission of Matters to a Vote of Security Holders

GENELUX Corp (GNLX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001231457 0001231457 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

GNLX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning GNLX (GENELUX Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.

Recent GNLX coverage spans financial news, insider activity and earnings.

In the last 30 days, GNLX insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($9K). The most active reporter was Yu Yong, Chief Scientific Officer, with 1 filing.

What's driving GNLX

  • The update is primarily a cash runway and burn-rate signal, which can pressure biotech risk appetite until the next clinical data catalyst.

    tradingview.com · Nov 16, 2026

  • Routine shareholder-meeting outcomes; limited direct implications beyond governance/audit confirmation.

    SEC EDGAR 8-K · Jun 22, 2026

  • An insider sale disclosed via Form 4 is typically low-signal for fundamentals, but can slightly affect near-term sentiment.

    SEC EDGAR · Jun 5, 2026

  • Insider selling disclosed via Form 4; likely limited fundamental signal given pre-arranged 10b5-1, but can affect near-term sentiment/flow.

    SEC EDGAR · Jun 3, 2026

  • The insider selling by Yu Yong, SVP of Genelux, coincides with a significant share price decline and weak financial health, indicating potential negative sentiment.

    Investing.com Australia · Mar 27, 2026

AlphAI scores every news story that mentions GNLX with an AI model for sentiment and relevance, and aggregates insider trades from GENELUX Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GNLX

Score
$GNLXLowShareholder vote

GENELUX Corp (GNLX): Submission of Matters to a Vote of Security Holders

GENELUX Corp (GNLX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001231457 0001231457 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Genelux stock falls after announcing proposed public offering By Investing.com

Genelux Corp (NASDAQ:GNLX) stock dropped 10.3% in after-hours trading following the announcement of a proposed underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of shares, with Lucid Capital Markets acting as the sole book-running manager. Genelux, a clinical-stage immuno-oncology company, did not disclose the terms or size of the offering, which is subject to market conditions.

Related tickers